Rilpivirine adverse reactions: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
Line 7: Line 7:
The following adverse drug reactions (ADRs) are discussed in greater detail in other sections of the package insert:
The following adverse drug reactions (ADRs) are discussed in greater detail in other sections of the package insert:


*Depressive Disorders [see Warnings and Precautions]
*[[Depressive Disorders]] [see Warnings and Precautions]
*Hepatotoxicity [see Warnings and Precautions ]
*[[Hepatotoxicity]] [see Warnings and Precautions ]


===Clinical Trials Experience===
===Clinical Trials Experience===
Line 37: Line 37:


====Hepatobiliary Disorders====
====Hepatobiliary Disorders====
Cholecystitis, cholelithiasis
[[Cholecystitis]], [[cholelithiasis]]


====Metabolism and Nutrition Disorders====
====Metabolism and Nutrition Disorders====
Line 49: Line 49:


====Renal and Urinary Disorders====
====Renal and Urinary Disorders====
Glomerulonephritis membranous, glomerulonephritis mesangioproliferative, nephrolithiasis
[[Glomerulonephritis membranous]], [[glomerulonephritis mesangioproliferative]], [[nephrolithiasis]]


====Laboratory Abnormalities in Treatment-Naïve Subjects====
====Laboratory Abnormalities in Treatment-Naïve Subjects====
Line 78: Line 78:
====Serum Lipids====
====Serum Lipids====


Changes from baseline in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides are presented in Table 3. The clinical benefit of these findings has not been demonstrated.
Changes from baseline in [[total cholesterol]], [[LDL-cholesterol]], [[HDL-cholesterol]] and [[triglycerides]] are presented in Table 3. The clinical benefit of these findings has not been demonstrated.




Line 98: Line 98:
====Renal and Genitourinary Disorders====
====Renal and Genitourinary Disorders====
Nephrotic syndrome<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = EDURANT (RILPIVIRINE HYDROCHLORIDE) TABLET, FILM COATED [JANSSEN PRODUCTS, LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03880372-2c68-45c6-a53a-f420c49541d6 | publisher =  | date =  | accessdate = }}</ref>
Nephrotic syndrome<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = EDURANT (RILPIVIRINE HYDROCHLORIDE) TABLET, FILM COATED [JANSSEN PRODUCTS, LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=03880372-2c68-45c6-a53a-f420c49541d6 | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 00:55, 10 January 2014

Rilpivirine
EDURANT® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Adverse Reactions

The following adverse drug reactions (ADRs) are discussed in greater detail in other sections of the package insert:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety assessment is based on the Week 96 pooled data from 1368 patients in the Phase 3 controlled trials TMC278-C209 (ECHO) and TMC278-C215 (THRIVE) in antiretroviral treatment-naïve HIV-1 infected adult patients, 686 of whom received EDURANT (25 mg once daily) [see Clinical Studies]. The median duration of exposure for patients in the EDURANT arm and efavirenz arm was 104.3 and 104.1 weeks, respectively. Most ADRs occurred in the first 48 weeks of treatment. The proportion of subjects who discontinued treatment with EDURANT or efavirenz due to ADR, regardless of severity, was 2% and 4%, respectively. The most common ADRs leading to discontinuation were psychiatric disorders: 10 (1%) subjects in the EDURANT arm and 11 (2%) subjects in the efavirenz arm. Rash led to discontinuation in 1 (0.1%) subject in the EDURANT arm and 10 (1.5%) subjects in the efavirenz arm.

Common Adverse Drug Reactions

ADRs of at least moderate intensity (≥ Grade 2) reported in at least 2% of adult subjects are presented in Table 1. Selected treatment-emergent laboratory abnormalities are included in Table 2.

[[File:|800px|thumb]]


No new ADR terms were identified in adult subjects in the Phase 3 TMC278-C209 and TMC278-C215 trials between 48 weeks and 96 weeks nor in the Phase 2b TMC278-C204 trial through 240 weeks. The incidence of adverse events in the Phase 2b TMC278-C204 trial was similar to the Phase 3 trials through 96 weeks.

Less Common Adverse Drug Reactions

Treatment-emergent ADRs of at least moderate intensity (≥ Grade 2) occurring in less than 2% of antiretroviral treatment-naïve subjects receiving EDURANT are listed below by System Organ Class. Some adverse events have been included because of investigator's assessment of potential causal relationship and were considered serious or have been reported in more than 1 subject treated with EDURANT.

Gastrointestinal Disorders

Diarrhea, abdominal discomfort

Hepatobiliary Disorders

Cholecystitis, cholelithiasis

Metabolism and Nutrition Disorders

Decreased appetite

Nervous System Disorders

Somnolence

Psychiatric Disorders

Sleep disorders, anxiety

Renal and Urinary Disorders

Glomerulonephritis membranous, glomerulonephritis mesangioproliferative, nephrolithiasis

Laboratory Abnormalities in Treatment-Naïve Subjects

The percentage of subjects treated with EDURANT or efavirenz in the Phase 3 trials with selected treatment-emergent clinical laboratory abnormalities (Grades 1 to 4), representing worst Grade toxicity are shown in Table 2.

[[File:|800px|thumb]]
[[File:|800px|thumb]]


Adrenal Function

In the pooled Phase 3 trials, at Week 96, there was an overall mean change from baseline in basal cortisol of -19.1 (-30.87; -7.39) nmol/L in the EDURANT group and of +0.1 (-12.63; 12.80) nmol/L in the efavirenz group. At Week 96, the mean change from baseline in ACTH-stimulated cortisol levels was lower in the EDURANT group (+18.4 ± 8.36 nmol/L) than in the efavirenz group (+54.1 ± 7.24 nmol/L). Mean values for both basal and ACTH-stimulated cortisol values at Week 96 were within the normal range. Overall, there were no serious adverse events, deaths, or treatment discontinuations that could clearly be attributed to adrenal insufficiency.

Serum Creatinine

In the pooled Phase 3 trials, an increase in serum creatinine was observed over the 96 weeks of treatment with EDURANT. Most of this increase occurred within the first four weeks of treatment, with a mean change of 0.1 mg/dL (range: -0.3 mg/dL to 0.6 mg/dL) observed after 96 weeks of treatment. In subjects who entered the trial with mild or moderate renal impairment, the serum creatinine increase observed was similar to that seen in subjects with normal renal function. These changes are not considered to be clinically relevant and no subject discontinued treatment due to increases in serum creatinine. Serum creatinine increases occurred regardless of the background N(t)RTI regimen.

Serum Lipids

Changes from baseline in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides are presented in Table 3. The clinical benefit of these findings has not been demonstrated.


[[File:|800px|thumb]]


Subjects co-infected with hepatitis B and/or hepatitis C virus

In subjects co-infected with hepatitis B or C virus receiving EDURANT, the incidence of hepatic enzyme elevation was higher than in subjects receiving EDURANT who were not co-infected. This observation was the same in the efavirenz arm. The pharmacokinetic exposure of rilpivirine in co-infected subjects was comparable to that in subjects without co-infection.

Postmarketing Experience

Adverse reactions have been identified during post-marketing in patients receiving a rilpivirine containing regimen. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Renal and Genitourinary Disorders

Nephrotic syndrome[1]

References

  1. "EDURANT (RILPIVIRINE HYDROCHLORIDE) TABLET, FILM COATED [JANSSEN PRODUCTS, LP]".

Adapted from the FDA Package Insert.